Systemic HRT vs. Vaginal Estrogen: Which Approach May Be Right for You?
Systemic estrogen (pills, patches, gels, sprays) is the option labeled for hot flashes and night sweats; low-dose vaginal estrogen (inserts, rings, creams) is labeled only for vaginal and vulvar atrophy, the dryness, burning and painful sex that follow menopause. If vaginal symptoms are your only problem, the Climara patch label itself tells prescribers to "first consider the use of topical vaginal products." The two differ sharply in how much estradiol reaches the blood: in their own label studies, a 0.05 mg/day Climara patch gave an average of 41 pg/mL, while Vagifem 10 mcg gave 5.5 pg/mL after 12 weeks. Yet the labels we opened for both still carry the same boxed warning and the same list of people who should not use them. Below is how they compare on labeled use, blood levels, the uterus question, warnings and what each costs online.
Updated · By Treatment Comparison Editorial Team · Sources and scope
Sources: DailyMed (NLM): Climara label · DailyMed (NLM): Vagifem label · MedlinePlus: MedlinePlus: estrogen · Menopause (journal), via Europe PMC: Menopause Society 2022 position statement · Menopause (journal), via Europe PMC: Menopause Society 2020 GSM statement · FDA: FDA February 2026 label changes
Start with the symptom you want treated
| Symptom or goal | Systemic estradiol (Climara patch) | Vaginal estradiol (Vagifem insert) |
|---|---|---|
| Hot flashes and night sweats | Labeled (moderate to severe) | Not labeled |
| Vaginal dryness, burning, painful sex | Labeled, but the label says to first consider vaginal products if this is the only reason | Labeled (atrophic vaginitis due to menopause) |
| Preventing postmenopausal osteoporosis | Labeled, but the label says to first consider non-estrogen medicines | Not labeled |
Sources: DailyMed (NLM): Climara label · DailyMed (NLM): Vagifem label
How much estradiol reaches the blood
The Climara label reports average blood estradiol of 22 pg/mL with the 0.025 mg/day patch, 41 pg/mL with 0.05 mg/day and 87 pg/mL with 0.1 mg/day after a single application to the abdomen. The Vagifem label reports an average of 10.1 pg/mL on day 1 of 10 mcg inserts, 7.35 pg/mL on day 14 and 5.5 pg/mL on day 83, not corrected for each woman's baseline.
These numbers come from separate studies, so treat them as a rough scale rather than a direct comparison. The Vagifem label still states that systemic absorption occurs, which is why its warnings and contraindications match those of systemic products.
Sources: DailyMed (NLM): Climara label · DailyMed (NLM): Vagifem label
What the trials on the systemic label found
In the Climara hot flush study (214 women randomized, 191 analyzed), the weekly hot flush rate fell 67% with 0.05 mg/day and 72% with 0.1 mg/day, compared with 18.1% on placebo; both doses differed from placebo at every treatment cycle. A separate study of 187 women found 0.025 mg/day statistically better than placebo at weeks 4 and 12 for frequency and severity of moderate to severe hot flashes.
Sources: DailyMed (NLM): Climara label
The same warnings appear on both labels
The Climara label (revised March 2026) and the Vagifem label (revised February 2024) both open with a boxed warning headed endometrial cancer, cardiovascular disorders, probable dementia and breast cancer. On February 12, 2026, FDA announced labeling changes for a first group of six hormone therapy products, including a topical vaginal estrogen, that removed cardiovascular disease, breast cancer and probable dementia statements from the boxed warning. More labels may change, so read the current label for the exact product you are prescribed.
MedlinePlus adds that estrogen raises the risk of endometrial cancer, that the risk grows the longer it is taken, and that women who have not had a hysterectomy are usually given a progestin with it.
Sources: DailyMed (NLM): Climara label · DailyMed (NLM): Vagifem label · MedlinePlus: MedlinePlus: estrogen · FDA: FDA February 2026 label changes
Who should not use either
- Abnormal genital bleeding that has not been diagnosed
- Breast cancer, a history of breast cancer, or another estrogen-dependent cancer
- A current or past blood clot in the legs or lungs
- A current or past stroke or heart attack
- Liver disease
- Protein C, protein S or antithrombin deficiency, or another known clotting disorder
- A past allergic reaction to the product
Sources: DailyMed (NLM): Climara label · DailyMed (NLM): Vagifem label
What the Menopause Society recommends
The 2022 hormone therapy statement calls hormone therapy the most effective treatment for hot flashes and for genitourinary syndrome of menopause, says risks differ by type, dose, duration, route, timing and whether a progestogen is used, and recommends low-dose vaginal estrogen or alternatives for genitourinary symptoms that over-the-counter products do not relieve.
The 2020 genitourinary statement says lubricants and moisturizers may suffice for mild symptoms; that low-dose vaginal estrogen, vaginal DHEA, systemic estrogen and ospemifene are effective for moderate to severe symptoms; that endometrial safety beyond 1 year of vaginal estrogen is not established; and that women with breast cancer should involve their oncologist.
Sources: Menopause (journal), via Europe PMC: Menopause Society 2022 position statement · Menopause (journal), via Europe PMC: Menopause Society 2020 GSM statement
What it costs to get either one online
Alloy's price list on October 26, 2026 showed estradiol pills from $39.99 per month, estradiol gel and Evamist spray at $69.99 per month, estradiol patches at $100 per month, progesterone from $23 per month and estradiol vaginal cream at $119.97 per 3-month supply. Alloy says it is cash-pay, accepts FSA/HSA cards, ships free and serves all 50 states and D.C. Its pages do not say whether the vaginal cream is an FDA-approved product or compounded, so ask.
Midi Health says it is in-network with most major insurers and available in all 50 states; copays and deductibles may still apply, and it does not list self-pay prices on its homepage. Its sample care plans include HRT patches, estradiol cream and vaginal estrogen. A clinician must assess you before any prescription, and prices change, so confirm the ongoing total before you pay.
Sources: Alloy: Alloy solutions · Alloy: Alloy · Midi Health: Midi Health
| Feature | estradiol | vaginal-estrogen |
|---|---|---|
| Labeled uses | Moderate to severe hot flashes and night sweats, moderate to severe vulvar and vaginal atrophy, low estrogen from hypogonadism or ovarian failure, prevention of postmenopausal osteoporosis (Climara label) | Atrophic vaginitis due to menopause (Vagifem label). Not labeled for hot flashes or bone loss |
| Average blood estradiol in label studies | Climara 0.025 mg/day: 22 pg/mL; 0.05 mg/day: 41 pg/mL; 0.1 mg/day: 87 pg/mL (single application, abdomen) | Vagifem 10 mcg: 10.1 pg/mL on day 1, 5.5 pg/mL on day 83 (not corrected for baseline). Separate studies, not a head-to-head trial |
| Forms | Oral tablets, weekly or twice-weekly patches, gels and sprays | Vaginal inserts (Vagifem, Imvexxy), a 90-day ring (Estring) and vaginal cream |
| Progestogen if you have a uterus | The label says to consider adding a progestogen to reduce the risk of endometrial cancer | The Vagifem label says the same. The Menopause Society says endometrial safety beyond 1 year of vaginal estrogen has not been established. A clinician decides |
| Boxed warning (labels opened October 26, 2026) | Yes: endometrial cancer, cardiovascular disorders, probable dementia and breast cancer (Climara, revised March 2026) | Yes: the same four headings (Vagifem, revised February 2024). FDA began removing parts of these warnings product by product in February 2026 |
| Who should not use it | Undiagnosed genital bleeding, breast or estrogen-dependent cancer, past or current blood clots, stroke or heart attack, liver disease, clotting disorders | The same list appears on the Vagifem label |
| Example online price (Alloy, October 2026) | Estradiol pill from $39.99/mo, gel or Evamist spray $69.99/mo, patch $100/mo; progesterone from $23/mo if needed | Estradiol vaginal cream $119.97 per 3-month supply |
| Bone protection | Labeled to prevent postmenopausal osteoporosis, though the label says to consider non-estrogen medicines first | Not labeled for bone protection |
Choose estradiol if...
Systemic estrogen fits women whose main complaint is moderate to severe hot flashes or night sweats. In the Climara label's hot flush study, the weekly hot flush rate fell 67% with 0.05 mg/day and 72% with 0.1 mg/day, compared with 18.1% on placebo. The Menopause Society's 2022 position statement calls hormone therapy the most effective treatment for these symptoms and says it prevents bone loss and fracture, with the most favorable balance in women under 60 or within 10 years of menopause who have no contraindications. Systemic estrogen also treats vaginal atrophy, so one product may cover both problems. If you still have a uterus, expect your clinician to discuss adding a progestogen.
Choose vaginal-estrogen if...
Vaginal estrogen fits women whose symptoms are vaginal dryness, burning, itching or pain with sex, without bothersome hot flashes. The Menopause Society's 2020 statement says lubricants and moisturizers may be enough for mild symptoms, and lists low-dose vaginal estrogen among effective options for moderate to severe ones. Blood estradiol stays far lower than with a systemic patch, but the label still says systemic absorption occurs and lists the same contraindications as systemic products. It does not treat hot flashes and is not labeled to protect bone. If you have had breast cancer, the 2020 statement says safety is not well established and your oncologist should be involved.
The Verdict
Choose by symptom, not by which option sounds milder. For hot flashes and night sweats, systemic estrogen is the labeled treatment and the Menopause Society calls hormone therapy the most effective one. For vaginal symptoms alone, the systemic patch label itself points prescribers to vaginal products first, and blood levels with a 10 mcg insert are a fraction of a patch's. Both carry the same contraindications and, on the labels we opened, the same boxed warning, so the same health history questions apply to either. A clinician who knows your history, uterus status and age at menopause should make the call.
Frequently Asked Questions
Sources and editorial notes
Medicine facts, blood levels and trial numbers come from the Climara and Vagifem labels on DailyMed, MedlinePlus, FDA and the Menopause Society's 2020 and 2022 position statements, checked on 2026-10-26. Prices come from Alloy's and Midi Health's public pages that day. We did not order or verify a personalized price. No clinician review is claimed.
Content updated . Source checking is editorial work; it is not a clinical review.
- DailyMed (NLM): Climara (estradiol transdermal system) prescribing informationMedical or regulatory reference · Accessed 2026-10-26
- DailyMed (NLM): Vagifem (estradiol vaginal inserts) prescribing informationMedical or regulatory reference · Accessed 2026-10-26
- MedlinePlus: EstrogenMedical or regulatory reference · Accessed 2026-10-26
- Menopause (journal), via Europe PMC: The 2022 hormone therapy position statement of The North American Menopause SocietyMedical or regulatory reference · Accessed 2026-10-26
- Menopause (journal), via Europe PMC: The 2020 genitourinary syndrome of menopause position statement of The North American Menopause SocietyMedical or regulatory reference · Accessed 2026-10-26
- FDA: FDA approves labeling changes for menopausal hormone therapy productsMedical or regulatory reference · Accessed 2026-10-26
- Alloy: Alloy solutions and pricesProvider-reported product information · Accessed 2026-10-26
- Alloy: Alloy menopause careProvider-reported product information · Accessed 2026-10-26
- Midi Health: Midi Health menopause careProvider-reported product information · Accessed 2026-10-26